

ASX / MEDIA ANNOUNCEMENT

5 June 2020

Share Trading Policy – updated

Respiri Limited (ASX:RSH) (“Respiri” or the “Company”), an eHealth SaaS Company supporting respiratory health management, wishes to release a copy of the Company’s Share Trading Policy. Refer attachment below.

A copy of this Share Trading policy is also included on the Company’s website under the Investors - Corporate Governance section.

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respiri Limited
P: +61 408 462 873
E: marjan@respiri.co

Mr Nicholas Smedley
Executive Chairman
Respiri Limited
P: +61 447 074 160
E: nicholas@respiri.co

This ASX announcement dated 5 June 2020 has been authorised for release by the Board of Directors of Respiri Limited.

About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. The only platform of its kind, the flagship wheezo® product employs machine learning to provide personalised feedback and education based on the user's personal health data correlated with environmental factors, and enables the sharing of that data, anytime, anywhere with caregivers, physicians and other health care professionals.

Respiri’s mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited's operations are based in Melbourne, Australia.

For additional information about Respiri and its products, please visit www.respiri.co

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respiro current expectations, estimates and projections about the industry in which Respiro operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiro, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respiro cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respiro only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiro will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.



RESPIRI LIMITED SHARE TRADING POLICY

12TH MAY 2020

1. SUMMARY OF THIS POLICY

- 1.1.** This policy is designed to ensure that public confidence in Respiri Limited is maintained. It would be damaging to Respiri Limited's reputation if the market or the general public perceived that Respiri Limited persons might be taking advantage of their position to make financial gains (by dealing in securities on the basis of confidential or undisclosed inside information).
- 1.2.** Respiri Limited persons must not deal in Respiri Limited securities if they are aware of undisclosed inside information. Restrictions also apply to dealings in other company securities.
- 1.3.** Additional restrictions apply to "Designated Persons" which includes the following:
- i.** The Chairman of Respiri Limited; or
 - ii.** An Executive Director of Respiri Limited; or
 - iii.** A Non-executive Director of Respiri Limited; or
 - iv.** The Managing Director/CEO ("CEO"); or
 - v.** The Chief Financial Officer ("CFO"); or
 - vi.** An employee who reports to either the CEO or the CFO; or
 - vii.** Other persons who regularly possess undisclosed inside information or are nominated by the CEO.
- 1.4.** Specifically, these persons are not permitted to trade in Respiri Limited shares unless it is in a trading window. The **five** trading windows are post release of the annual results; post release of the September, December and March quarterly results and post the AGM, as follows:
- i.** a 15-day period commencing 24 hours after the announcement of Respiri Limited's annual results to the Australian Securities Exchange; and

- ii. a 15-day period commencing 24 hours after the announcement of Respiri Limited's September quarter results to the Australian Securities Exchange; and
- iii. a 15-day period commencing 24 hours after the announcement of Respiri Limited's December quarter results to the Australian Securities Exchange; and
- iv. a 15-day period commencing 24 hours after the announcement of Respiri Limited's March quarter results to the Australian Securities Exchange; and
- v. a 15-day period commencing 24 hours after the announcement of Respiri Limited's June quarter results to the Australian Securities Exchange; and
- vi. a 15-day period commencing 24 hours after Respiri Limited's Annual General Meeting; and any other period that the Board specifies from time to time,

1.5. Designated Persons are not permitted to elect to participate in share plans outside a trading window (unless participation is made conditional upon shareholder approval).

1.6. The above restrictions also apply to Designated Person's family or other related parties.

1.7. Key Management Personnel ("KMP") must seek approval before trading in shares, even in a trading window. This is discussed in more detail below.

2. INTRODUCTION

2.1. The Corporations Act prohibits the trading in shares, options and other securities ("securities") of a company by any person who is in possession of undisclosed price sensitive information regarding that company. The Corporations Act imposes substantial penalties on persons who breach those provisions.

2.2. The Corporations Act prohibits the trading in shares, options and other securities ("securities") of a company by any person who is in possession of undisclosed price sensitive information regarding that company. The Corporations Act imposes substantial penalties on persons who breach those provisions.

2.3. This policy regulates dealings by the directors, officers, senior executives and employees in securities in Respiri Limited and its related entities ("Respiri Limited") or outside companies about which they acquire undisclosed price-sensitive information ("inside information") through their position with Respiri Limited.

3. PURPOSE

3.1. The purpose of this policy is to ensure that Respiri Limited's directors, officers, consultants, advisers, senior management and other employees ("Respiri Limited persons") are aware of and abide by the legal restrictions on trading securities while in possession of inside information.

3.2. This policy is designed to ensure that public confidence in Respiri Limited is maintained. It would be damaging to Respiri Limited's reputation if the market or the general public perceived that employees might be taking advantage of their position to make financial gains (by dealing in securities on the basis of confidential information). Respiri Limited persons should consider the impact on Respiri Limited's reputation before entering into any dealing in Respiri Limited securities and should not proceed with any dealing they believe could adversely affect public confidence in Respiri Limited.

4. INSIDER TRADING

4.1. No person who has inside information about a company may:

- i. buy or sell securities in a company, or enter into an agreement to buy or sell securities, or exercise options over securities, or otherwise apply for, acquire, or dispose of securities;
- ii. encourage someone else to deal in securities in that company; or
- iii. directly or indirectly provide that information to another person where they know, or ought to know, that the person is likely to deal in securities or encourage someone else to deal in securities of that company.

These restrictions apply to all securities, not just Respiri Limited's securities.

Respiri Limited persons must not communicate price-sensitive information or cause that information to be communicated to another person other than for Respiri Limited's business purposes, and then only subject to appropriate confidentiality arrangements.

5. RESTRICTIONS ON TRADING

- 5.1.** Sections 5.3, 5.5 and 5.6 of this policy apply only to Respiri Limited's directors, the Managing Director/CEO ("CEO"), Chief Financial Officer ("CFO"), direct reports to the CEO and CFO, employees having regular access to confidential communication (including but not limited to Respiri Limited business unit or consolidated monthly management reports and forecasts), and such other persons as the CEO nominates (each a "Designated Respiri Limited Person").
- 5.2.** Sections 5.3, 5.5 and 5.6 also apply to trading by close family members or entities who a Designated Respiri Limited Person may control or influence (a "Connected Person").
- 5.3.** Designated Respiri Limited Persons must take appropriate steps to ensure that their Connected Persons do not breach this policy.
- 5.4.** Subject to the clearance process set out in section 5.4, and unless otherwise authorised by the Board, each Designated Respiri Limited Person and their Connected Persons, may only buy or sell Respiri Limited's securities during any of the following five periods (each a "trading window"):
- i. a 15-day period commencing 24 hours after the announcement of Respiri Limited's annual results to the Australian Securities Exchange; and
 - ii. a 15-day period commencing 24 hours after the announcement of Respiri Limited's September quarter results to the Australian Securities Exchange; and
 - iii. a 15-day period commencing 24 hours after the announcement of Respiri Limited's December quarter results to the Australian Securities Exchange; and
 - iv. a 15-day period commencing 24 hours after the announcement of Respiri Limited's March quarter results to the Australian Securities Exchange; and
 - v. a 15-day period commencing 24 hours after the announcement of Respiri Limited's June quarter results to the Australian Securities Exchange; and
 - vi. a 15-day period commencing 24 hours after Respiri Limited's Annual General Meeting; and any other period that the Board specifies from time to time,

- vii. and only where the person is not in possession of any inside information. All other periods are "closed periods" within the meaning of ASX Listing Rule 12.12.

5.5. Additional clearance requirements apply to Respiri Limited's KMP. For Respiri Limited, this includes all the Directors of Respiri Limited, the CEO and CFO ("KMP"). KMP must obtain clearance for any proposed dealings in Respiri Limited's securities and the following principles will apply:

- i. Respiri Limited's directors (other than the Chairman) must advise and obtain clearance from the Chairman (or his/her delegate) of a proposed trade in Respiri Limited's securities prior to any trade and confirm they are not in possession of any unpublished price-sensitive information.
- ii. Respiri Limited's Chairman must advise and obtain clearance from a majority of other directors of a proposed trade in Respiri Limited's securities prior to any trade and confirm they are not in possession of any unpublished price-sensitive information.
- iii. All other KMP must advise and obtain clearance from the Company Secretary of a proposed trade in Respiri Limited's securities, prior to any trade and confirm they are not in possession of any unpublished price sensitive information.
- iv. A request for clearance to trade will be answered as soon as practicable.
- v. Any clearance to trade can be given, refused, or have conditions imposed on the dealing by the approver in their discretion.
- vi. The approver may consult with other directors or members of management in order to determine whether there is a legal or reputational reason why the trade should not occur.
- vii. Clearance will only be effective for 3 business days.
- viii. KMP must promptly notify the Company Secretary in writing of any dealings in Respiri Limited's securities, ideally by close of business on the day of the trade.

5.6. In exceptional circumstances, for example, in the case of financial hardship or compulsion by court order, the CEO (or, in the case of directors, the Chairman) has discretion to grant clearance to deal in Respiri Limited's securities during a closed period. Such clearance must be given in writing prior to the relevant dealing and following such inquiries as the approver thinks necessary. There is no discretion to grant clearance for dealings by any person in possession of inside information.

5.7. Designated Respiri Limited Persons are prohibited from:

- i. dealing at any time in financial products such as options, warrants, derivatives, futures or other financial products issued over Respiri Limited's securities by third parties such as banks, and other institutions;
- ii. entering into transactions in products associated with Respiri Limited's securities which operate to limit the economic risk of their security holding in Respiri Limited (e.g. hedging arrangements) including Respiri Limited securities held beneficially (including, for example, in trust or under any Respiri Limited incentive plan) on that Respiri Limited person's behalf; and
- iii. engaging in short-term (less than 90 days) or speculative trading of Respiri Limited's securities at any time.

6. DEALINGS EXCLUDED FROM THIS POLICY

6.1. Sections 5.3 to 5.5 of this policy do not apply to:

- i. subject to section 7, an acquisition of securities under an employee incentive scheme or Dividend
- ii. Reinvestment Plan operated by Respiri Limited;
- iii. an acquisition or disposal of securities under a takeover of corporate action open to all shareholders (e.g.: pro-rata rights issues, share purchase plan or equal access buy-back);
- iv. dealings that result in no effective change to the beneficial interest in the securities (for example, transfers of securities already held into a superannuation fund or trust of which the Designated Respiri Limited Person or Connected Person is a beneficiary); and
- v. trading under a pre-approved non-discretionary trading plan, where the Designated Respiri Limited Person or Connected Person does not enter into the plan or amend the plan during a closed period, the plan does not permit the Designated Respiri Limited Person or Connected Person to exercise any influence or discretion in relation to trading under the plan and the plan cannot be cancelled during a closed period, other than in exceptional circumstances.

However, such dealings remain subject to the insider trading rules summarised in Section 4.

7. SHARE PLANS AND DIVIDEND REINVESTMENT PLAN

Designated Respiri Limited persons may only make application to join, withdraw from, or vary their participation in any Respiri Limited Dividend Reinvestment Plan or participate, or alter the basis of their participation in, any Respiri Limited share plan (including withdrawing shares from a share plan trust) during one of the above trading windows and may not do so if they possess inside information about Respiri Limited.

8. MARGIN LENDING ARRANGEMENTS

Entry into a margin loan or other secured financing arrangement is a dealing regulated by this policy (including the clearance requirements in section 5.4 for KMP).

Designated Respiri Limited Persons are prohibited from entering into a direct margin loan or other secured financing arrangements over Respiri Limited securities (as opposed to indirect margin loans or other secured financing arrangements entered into by third party administered funds).

Designated Respiri Limited Persons must take all reasonable steps to ensure that dealings in Respiri Limited securities pursuant to a margin loan or other secured financing arrangement (including dealings of their Connected Persons) occur in accordance with this policy.

An involuntary disposal of Respiri Limited securities that occurs as a result of a margin lender or financier exercising its rights in relation to Respiri Limited securities will not result in a breach of this policy provided the Designated Respiri Limited Person took any reasonable steps available to procure compliance with this policy.

9. BREACH OF THIS POLICY

A breach of this policy will be regarded as serious and may lead to disciplinary action, including dismissal.

10. FURTHER INFORMATION

If you require any further information or are uncertain about the application of the law or this trading policy in any situation, please contact the Company Secretary.